Flexion Therapeutics — Q1 2021 Earnings Presentation
7 slides from Flexion Therapeutics's earnings presentation, Apr 13, 2021
Slide 1: Q1 2021 Commercial Metrics
Q1 2021 Commercial Metrics April 13, 2021 Exhibit 99.2
Slide 2: Commercial Metrics Overview
Commercial Metrics Overview 2 Preliminary ZILRETTA® net sales of $24.6 million in Q1 2021 4,417 accounts had purchased ZILRETTA as of March 31, 2021; up from 4,248 as of December 31, 2020 3,470 accounts had re-ordered ZILRETTA (79% of accounts that had purchased), as of March 31, 2021; up from 3,321
Slide 3: ZILRETTA Net Sales Quarterly Since Launch
ZILRETTA Net Sales Quarterly Since Launch 3 Note: Flexion recognizes ZILRETTA sales upon receipt of product by specialty distributors and pharmacies.
Slide 4: Distribution of Accounts by ZILRETTA Purchases
Distribution of Accounts by ZILRETTA Purchases Cumulative 4 Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the
Slide 5: Distribution of ZILRETTA Purchases by Accounts
5 Distribution of ZILRETTA Purchases by Accounts Cumulative Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the
Slide 6: ZILRETTA Purchases by New and Existing Accounts
ZILRETTA Purchases by New and Existing Accounts Cumulative 6 Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the
Slide 7: Flexion: Transformative Medicine... Where It Matters
cleion Transformative Medicine... Where It Matters